A phase II, randomised, double-blind, placebo controlled, parallel group, dose-finding clinical trial to investigate the efficacy and safety of 10 and 20 mg/day aerosolised liposomal ciclosporin A (L-CsA) versus placebo in the treatment of bronchiolitis obliterans syndrome (BOS) in allogeneic haematopoietic stem cell transplant (HSCT) patients
Latest Information Update: 30 Sep 2017
At a glance
- Drugs Ciclosporin (Primary)
- Indications Bronchiolitis obliterans
- Focus Adverse reactions; Therapeutic Use
- 15 Aug 2012 New trial record